Researchers shed new light on the development of glioblastoma

2 May 2012

New research has looked to have expanded the knowledge that medical professionals have on one of the most common and deadliest forms of brain cancer.

Alfredo Quinones-Hinojosa, an associate professor of neurosurgery and oncology at the Johns Hopkins University School of Medicine, has led a study which involved the analysis of glioblastoma.

A type of glial tumour, the condition has been identified in the majority of primary brain tumours diagnosed in the US and was brought into the public light when Senator Ted Kennedy contracted and ultimately died from the disease.

However, Mr Quinones-Hinojosa and company believe they have discovered a protein which could hold the key to how glioblastoma moves and invades healthy brain tissue.

"If we could catch these cells before they take off into other parts of the brain, we could make malignant tumours more manageable, and improve life expectancy and quality of life," Mr Quinones-Hinojosa stated.

The study, which has been published in the journal PLoS Biology, also highlighted that a cheap FDA-approved drug, called diuretic bumetanide, is already on the market which could impact the movement of glioblastoma cells.

Posted by Edward Bartel

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)